PE: How do global pharma growth strategies differ from domestic strategies? Ackerman: There are two different models for ...
Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their ...
Stanton’s research, including the 2023 HBS case “Generative AI and the Future of Work,” underscores a pivotal truth: AI will not eliminate jobs en masse in the near term, but it will reshape them, ...
Olympia Pharmaceuticals expanded into Mississippi, now licensed in 49 states, enhancing access to compounded pharmaceuticals and manufacturing capabilities. The company's strategy emphasizes ...
Merck's acquisition of Cidara Therapeutics for $9.2 billion focuses on CD388, a promising antiviral for influenza prevention.
Both The U.S. Department of Health and Human Services (HHS) and the FDA announced the appointment of Richard Pazdur, M.D., as ...
FDA Commissioner Marty Makary announced FDA’s plans for a new drug approval pathway named the Plausible Mechanism Pathway ...
Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how events from the past ...
Jay Lalezari, CEO of CytoDyn, explains how the CCR5 receptor has emerged as a pivotal target in metastatic cancers due to its ...
In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA ...
Per the FDA's request, HHS is updating hormone therapy labels, removing misleading warnings to empower women in managing ...
How effective is Wegovy at treating MASH? Novo Nordisk announced the results of the ESSENCE phase 3 trial at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results